Sander van Deventer, VectorY & Forbion | Pioneering gene therapy | E11

Flot.bio x Philip Hemme

We’re in Amsterdam with Sander van Deventer, the CEO of VectorY. We will talk about VectorY and what’s missing in gene therapy. 💎 ABOUT THE SPEAKER Sander has an impressive track record, being a professor, operational biotech founder and a VC. In 1998, he co-founded uniQure, which brought the first gene therapy to the market. He also co-founded the leading VC Forbion as well as Dezima. He is now building a new venture VectorY, again in gene therapy. I interviewed him in 2017 back at Labiotech so it’s great to catch up with him again. 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/sander-van-deventer-gene-therapy/ 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 10k monthly views. Free. ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact [e-mail] and unlock sponsorship opportunities in our podcasts! 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. ⏰ TIMESTAMPS [00:00:00] Intro [00:01:54] VectorY: Raising the largest Series A in 2023 in 🇪🇺 [00:05:01] What's coming for ALS [00:07:50] How Vectorized Antibodies work [00:17:57] New Vector (AAV) technologies [00:22:55] The pipeline of VectorY [00:27:22] Where VC money is moving to [00:32:29] The Netherlands as a biotech cluster [00:35:31] CRISPR approval and gene therapy reimbursement [00:48:15] Where Sander came from [00:56:14] How to have the energy to be a serial entrepreneur